Skip to main content
Defence Therapeutics Inc. logo

Defence Therapeutics Inc. — Investor Relations & Filings

Ticker · DTC ISIN · CA24463V1013 CSE Manufacturing
Filings indexed 195 across all filing types
Latest filing 2024-03-04 Regulatory Filings
Country CA Canada
Listing CSE DTC

About Defence Therapeutics Inc.

https://defencetherapeutics.com/

Defence Therapeutics Inc. is a biotechnology company focused on developing advanced cancer therapeutics by enhancing drug delivery. Its core technology is the proprietary Accum® platform, a precision intracellular drug-delivery system designed to overcome endosomal entrapment and ensure therapeutic agents reach their cellular targets. Accum® is applied to significantly boost the efficacy and safety of various biologics, including Antibody-Drug Conjugates (ADCs), Radiopharmaceuticals (Radioimmune Conjugates or rADCs), and vaccines. Preclinical models demonstrate that Accum® can increase the potency of enhanced therapies up to 60-fold, enabling safer and more effective first-line treatments. The company utilizes a licensing model for its ADC enhancement technology and actively develops novel radioimmune conjugate assets, aiming to transform existing and next-generation oncology treatments.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2024-03-04 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2024-02-29 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2024-02-29 English
Interim MD&A - English.pdf
Regulatory Filings
2024-02-29 English
Interim financial statements/report – English.pdf
Regulatory Filings
2024-02-29 English
Material change report - English.pdf
Regulatory Filings
2024-02-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.